- Home
- SILC vs CABA Comparison
SILC vs CABA Comparison
Compare SILC & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- CABA
- Stock Information
- Founded
- SILC 1987
- CABA 2017
- Country
- SILC Israel
- CABA United States
- Employees
- SILC N/A
- CABA N/A
- Industry
- SILC Computer Manufacturing
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SILC Technology
- CABA Health Care
- Exchange
- SILC Nasdaq
- CABA Nasdaq
- Market Cap
- SILC 104.7M
- CABA 118.8M
- IPO Year
- SILC 1994
- CABA 2019
- Fundamental
- Price
- SILC $16.60
- CABA $2.06
- Analyst Decision
- SILC Hold
- CABA Strong Buy
- Analyst Count
- SILC 2
- CABA 8
- Target Price
- SILC N/A
- CABA $26.13
- AVG Volume (30 Days)
- SILC 16.6K
- CABA 1.4M
- Earning Date
- SILC 01-30-2025
- CABA 03-20-2025
- Dividend Yield
- SILC N/A
- CABA N/A
- EPS Growth
- SILC N/A
- CABA N/A
- EPS
- SILC N/A
- CABA N/A
- Revenue
- SILC $58,114,000.00
- CABA N/A
- Revenue This Year
- SILC $6.22
- CABA N/A
- Revenue Next Year
- SILC $19.10
- CABA N/A
- P/E Ratio
- SILC N/A
- CABA N/A
- Revenue Growth
- SILC N/A
- CABA N/A
- 52 Week Low
- SILC $11.35
- CABA $1.76
- 52 Week High
- SILC $18.24
- CABA $24.85
- Technical
- Relative Strength Index (RSI)
- SILC 47.87
- CABA 38.28
- Support Level
- SILC $16.35
- CABA $2.03
- Resistance Level
- SILC $17.46
- CABA $2.90
- Average True Range (ATR)
- SILC 0.63
- CABA 0.24
- MACD
- SILC -0.09
- CABA -0.04
- Stochastic Oscillator
- SILC 17.11
- CABA 4.00
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters; Edge Networking Solutions; FPGA Based Cards; x86 Open Appliances Bypass Switches and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.